Understanding the risks of botanical-drug interactions
Open Access Government · 14.07.2026 · 51 (1) · 32-33
DOI: 10.56367/oag-051-12145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Access Government, erschienen am 14.07.2026. Verfasst von Erin C Berthold.
Abstract (Originalsprache)
Understanding the risks of botanical-drug interactions Dr. Erin C. Berthold emphasizes the importance of raising awareness and educating individuals about the potential risks associated with botanical supplements and their interactions with medications. The risks of botanical-drug interactions become greater as patients move away from the textbook average – someone with intact hepatic and renal function and a short or non-existent medication list. But the reality in clinical practice today is not so simple, and interactions that would produce minimal issues in a ‘healthy’ adult may be much more significant in vulnerable populations. These vulnerable populations include chemotherapy patients, older adults, and individuals with pre-existing conditions. Each of these populations has a physiology, pharmacology, or pathology that may narrow the therapeutic margin of a drug even before a botanical supplement is added.
Zitieren
APA
Berthold, E. C. (2026). Understanding the risks of botanical-drug interactions. Open Access Government, 51(1), 32-33. https://doi.org/10.56367/oag-051-12145
Vancouver
Berthold EC. Understanding the risks of botanical-drug interactions. Open Access Government. 2026;51(1):32-33. doi:10.56367/oag-051-12145
BibTeX
@article{Berthold2026,
author = {Berthold, Erin C},
title = {Understanding the risks of botanical-drug interactions},
journal = {Open Access Government},
year = {2026},
volume = {51},
number = {1},
pages = {32--33},
doi = {10.56367/oag-051-12145}
}
EUVIMED